ResMed Inc. has announced its financial results for the fiscal year ending June 30, 2025. The company reported a net revenue of $5,146.3 million, marking a 10% increase compared to the fiscal year 2024. Gross profit rose to $3,055.0 million, a 15% increase from $2,655.3 million in the previous year. Net income reached $1,400.7 million, up from $1,021.0 million in fiscal year 2024. Earnings per diluted share increased to $9.51 from $6.92. ResMed's business operations are segmented into Sleep and Breathing Health and Residential Care Software. The company continues to focus on developing innovative products, such as the new AirSense 11 device, which offers enhanced features like a touch screen and over-the-air update capabilities. These advancements are expected to support future growth by improving patient outcomes and creating efficiencies for healthcare providers. Total operating cash flow for fiscal year 2025 was $1,751.6 million, with cash and cash equivalents totaling $1,209.5 million as of June 30, 2025. The company also declared a quarterly dividend of $0.53 per share, resulting in a total dividend payout of $310.9 million for the year. ResMed's total assets were valued at $8.2 billion, with stockholders' equity amounting to $6.0 billion.